Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

On March 26, 2009, QLT Inc. announced the appointment of Ms. Kathryn Falberg to its board of directors and audit committee.

Ms. Falberg is currently Chief Financial Officer and Chief Operating Officer of ARCA biopharma and has over 20 years of experience as a financial executive and corporate director. Ms. Falberg's career includes seven years at Amgen, one of the world's largest biotechnology companies, where she served as Senior Vice President and Chief Financial Officer, as well as Vice-President, Controller and Chief Accounting Officer and Treasurer. She also served as Chief Financial Officer of Inamed, a medical device company which was later acquired by Allergan. Ms. Falberg currently serves as Chair of the audit committees for Halozyme and ESS Technology. Former directorships include Human Genome Sciences, Fresh Del Monte and VISX.

This appointment brings the number of directors on the Board to seven.

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
99.1 Press Release dated March 26, 2009

---